Carlos Marcelo de Barros, MD, PhD, FIPP

Prof. Dr. Carlos Marcelo de Barros, MD, PhD, FIPP

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
FSFabrício Gomes da Silva
Fabrício Gomes da Silva
MPMárcia Helena Miranda Cardoso Podestá
Márcia Helena Miranda Cardoso Podestá
TSThayná Coelho Silva
Thayná Coelho Silva
CFCarlos Marcelo de Barros, MD, PhD, FIPP
Carlos Marcelo de Barros, MD, PhD, FIPP
BCBreno Fialho Vitarelli de Carvalho
Breno Fialho Vitarelli de Carvalho
LTLarissa Helena Torres
Larissa Helena Torres

5 January 2024 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
YNYasmim Jianjulio Nassif
Yasmim Jianjulio Nassif
MZMaria Elisa Zanin
Maria Elisa Zanin
JMJoselin Valeska Martinez-Sobalvarro
Joselin Valeska Martinez-Sobalvarro
CFCarlos Marcelo de Barros, MD, PhD, FIPP
Carlos Marcelo de Barros, MD, PhD, FIPP
MPMaurílio Pacheco-Neto
Maurílio Pacheco-Neto
LTLarissa Helena Torres
Larissa Helena Torres

29 October 2026 in Pain Management Nursing
Verified
Journal Article
Open access
CSCremilson de Paula Silva
Cremilson de Paula Silva
APAngela Bezerra Soares Perlamagna
Angela Bezerra Soares Perlamagna
MSMarina Quintino Silva
Marina Quintino Silva
ABAlice Regina Costa Barbosa
Alice Regina Costa Barbosa
CFCarlos Marcelo de Barros, MD, PhD, FIPP
Carlos Marcelo de Barros, MD, PhD, FIPP
Ana Cláudia Mesquita GarciaAna Cláudia Mesquita Garcia
Ana Cláudia Mesquita Garcia

15 July 2023 in Journal of Pharmaceutical and Biological Sciences
Verified
Journal Article
Open access
PDF file
ASAlessandra Oliveira Silva
Alessandra Oliveira Silva
DMDanielle Aparecida de Oliveira Marrafon
Danielle Aparecida de Oliveira Marrafon
AAAna Flávia Amorim
Ana Flávia Amorim
CFCarlos Marcelo de Barros, MD, PhD, FIPP
Carlos Marcelo de Barros, MD, PhD, FIPP
RRRicardo Radighieri Rascado
Ricardo Radighieri Rascado
MPMarilia Gabriella Alves Goulart Pereira
Marilia Gabriella Alves Goulart Pereira
Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.

10 February 2024
Verified
Dataset
Closed access
PDF file
RCRavena Carolina de Carvalho
Ravena Carolina de Carvalho
ASAna Laura Silva
Ana Laura Silva
DPDanielle Cavalcante de Paula
Danielle Cavalcante de Paula
LGLaura Pereira Generoso
Laura Pereira Generoso
NCNatalie Lange Candido
Natalie Lange Candido
MSMarcelo Lourenço da Silva
Marcelo Lourenço da Silva
This research delves into the consequences of consistent pinprick stimulation on preterm offspring to ascertain its long-term implications for pain sensitivity. The primary objective of this protocol was to investigate the impact of neonatal pinprick stimuli on the pain threshold in the later stages of life using a preterm rat model. By establishing this model, we aim to advance the research on understanding and managing early postnatal pain associated with prematurity. The findings of this study indicate that while the baseline thresholds to mechanical stimuli remained unaffected, there was a notable increase in mechanical hypersensitivity following complete Freund's adjuvant (CFA) injection in adult rats. Interestingly, compared with male rats, female rats demonstrated heightened inflammatory hypersensitivity. Notably, maternal behavior, the weight of the litters, and the growth trajectory of the offspring remained unchanged by the stimulation. The manifestation of altered nociceptive responses in adulthood after neonatal painful stimuli could be indicative of changes in sensory processing and the functioning of glucocorticoid receptors. However, further research is needed to understand the underlying mechanisms involved and to develop interventions for the consequences of prematurity and neonatal pain in adults.

23 December 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
Roberto Salvador de Souza GuimarãesRoberto Salvador de Souza Guimarães
Roberto Salvador de Souza Guimarães
VGVictoria Ragognete Guimarães
Victoria Ragognete Guimarães
CFCarlos Marcelo de Barros, MD, PhD, FIPP
Carlos Marcelo de Barros, MD, PhD, FIPP
PBPereira Lima Brigagao Pereira Lima Brigagao
Pereira Lima Brigagao Pereira Lima Brigagao
Francisca RegoFrancisca Rego
Francisca Rego
Background/Objectives: Safe discharge after neurosurgical traumatic brain injury (TBI) depends on documented counseling and appropriate referrals, yet real-world fidelity is uncertain in resource-constrained settings. We quantified discharge process quality and identified digitally actionable gaps. Methods: The sample for this study was a retrospective cohort of 559 consecutive neurosurgical TBI patients discharged from a Brazilian public tertiary center (2012–2022). Data were abstracted from electronic health records. The primary outcome was documentation of warning sign counseling at discharge. Proportions are reported with exact Clopper–Pearson 95% confidence intervals. Results: The median age was 66 years (IQR 47–79.5); 78.5% were male and most received care under the public health system. Subdural hematoma predominated; hematoma drainage was the most frequent procedure. Warning sign counseling was documented in 16.1% of cases (89/559; 95% CI 13.2–19.5), and no palliative care referrals were recorded. Conclusions: A low baseline for a safety-critical discharge element exposes an immediately actionable target. Embedding discharge order sets with mandatory counseling fields in the EHR, clinical decision support prompts for palliative care screening and follow-up, and QR-coded patient handouts represent a pragmatic path to improve discharge quality and end-of-life readiness in the digital era.